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Articles reporting on the synthesis and biological activity of 3-hetarylchroman-4-ones are reviewed. 
The following preparative methods to 3-hetarylchroman-4-ones - nucleophilic substitution in 3-
bromochroman-4-ones, cyclization of 2-hydroxy-α-hetarylacetophenones, reduction/hydrogenation 
of 3-azahetarylchromones, their benefits and disadvantages are described. The biological activity of 
3-hetarylchromanones is also surveyed.  
________________________________________________________________________________ 
Introduction 
The flavonoids are related to numerous 
cluster of natural polyphenolic compounds. 
They are widely spread in plants and are known 
as biologically active compounds. Chromones 
and coumarines with their derivatives belong to 
the class of flavonoids.  
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Figure 1. Benzopyran-4-ones’ representatives. 
Natural chromones (benzopyran-4-ones) are 
represented in most cases by flavones (2-
arylbenzopyran-4-ones) and isoflavones (3-
arylbenzopyran-4-ones). The numeration of 
such system is also given in Figure 1. 
The replacement of aryl radical in the 
isoflavone molecules on such pharmacophores 
as nitrogen heterocycles leads to the new 
structures, named “double drugs”, which are 
potential bispharmacophoric medicine remedy – 
3-azahetarylchromones. The researches that 
have been reported on the 3-hetarylchromones 
are both extensive and varied [1-4]. The 
hydrogenated chromone derivatives are of 
indubitable interest, owing to a wide spectrum 
of biological activity (estrogenic, anti-cancer, 
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antiinflammatory, antioxidative, 
hepatoprotective, antimicrobial, hypolipidemic 
etc.) [5]. Considerable less information has been 
reported on the hydrogenated analogues of 3-
hetarylchromones. In this mini review, the 
authors make attempt to reflect up-to-date state 
of researches on 3-hetarylchroman-4-ones’ 
synthesis and biological activity. 
 
Results and discussion 
There are three basic approaches for 3-
hetarylchroman-4-ones’ preparation: 
nucleophilic substitution in 3-bromochroman-4-
ones, cyclization of 2-hydroxy-α-
hetarylacetophenones, reduction/hydrogenation 
of 3-hetarylchromones. 
1. Nucleophilic substitution in 3-bromo- 
chroman-4-ones 
It is possible to synthesize 3-
hetarylchroman-4-ones by nucleophilic 
substitution in 3-bromochroman-4-ones, 
although this method is of no practical 
significance for reasons that are discussed 
below. 
It is known that 3-bromochroman-4-ones 
readily eliminate hydrogen bromide in the 
presence of alkali to form chromones. It is 
interesting to note that treatment of 3-
bromochroman-4-one with diethylamine in 
aqueous solution at room temperature was 
reported to give the diethylaminovinyl ketone, 
which could be readily converted into chromone 
by the action of ethereal hydrogen chloride [6]. 
Colonge and Guyot [7] described the reaction of 
3-bromochroman-4-one 1 with piperidine and 
suggested the isolated product to be 3-
piperidinochroman-4-one 2 (Scheme 1). Further 
reinvestigation [8] indicated that the isolated 
compound was not 2, but identical with o–
hydroxy--piperidinoacrylophenone 3, obtained 
according to Winter and Hamilton [9] after 
treatment of chromone with piperidine. It can be 
assumed that the first step of the above reaction 
consists in the formation of chromone with 
subsequent production of 3. However, as the 
formation of 2 could not be excluded, the 
treatment of 1 was performed with the 
calculated amount (2 moles) of piperidine in dry 
benzene. After removal of the main product 3 
the expected piperidinochromanone 2 could be 
isolated as its hydrochloride in poor yield (8 %). 
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Scheme 1. The synthesis of 3-piperidinochroman-4-one.  
The synthesis of 3-(1H-imidazol-1-yl)chroman-
4-ones 4 was first attempted by reaction of the 
corresponding 3-bromochroman-4-ones 1 with 
excess of imidazole 5 in DMF (Scheme 2). 
Varying degrees of dehydrohalogenation of 3-
bromochroman-4-ones took place, giving the 
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corresponding chromones 6 in addition to the 
desired compounds of formula 4. The side 
reaction giving chromones 6 could not be 
eliminated by changing the solvent and 
temperature or by using imidazole derivatives 
such as its sodium or silver salt or 
trimethylsililimidazole [10]. 
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Scheme 2. The synthesis of 3-(1H-imidazol-1-yl) 
chroman-4-ones.  
 
The 3-(imidazol-1-yl)chroman-4-one series was 
obtained by modifying a substituent on the 
phenylene ring of the parent compounds (R 
group in Scheme 2) [11]. 
By reacting pyrazole with 3-
bromochroman-4-ones under similar conditions 
the unreacted materials were recovered [10]. 
The synthesis of 3-(1H-1,2,4-
triazol)chroman-4-one 7 was first attempted by 
reaction of the 3-bromochroman-4-one with an 
excess (3-5 moles) of 1,2,4-triazole by refluxing 
in DMF [12], a procedure similar to the one 
discribed by Strehlka et al. [13]. The latter 
reaction did not give desired 3-hetarylchroman-
4-one 7 and the starting material was recovered 
(98 %). When 1,2,4-triazole was reacted with 3-
bromochroman-4-one in the presence of K2CO3 
in MeCN, in a procedure similar to those 
reported by Lai et al. [14], dehydrohalogenation 
of 1 took place giving the chromone 6 as the 
major product and the compound 7 in 12 % 
yield (Scheme 3). 
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Scheme 3. The synthesis of 3-(1H-1,2,4-triazol-1-
yl)chroman-4-one. 
However, the compound 7 could be 
synthesized in high yield as shown in Scheme 4. 
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Scheme 4. The synthesis of 3-(1H-1,2,4-triazol-1-
yl)chroman-4-one. 
 
Reaction of 3-bromochroman-4-one 1 with 1-
amino-1,3,4-triazole 8 in MeCN under reflux 
for one day thus gave the desired triazolium salt 
9 in 76 % yield. The chromone 6 was isolated in 
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8 % yield as by-product. Diazotization of the 
salt 9 (with loss nitrous oxide) readily provided 
7 in good yield (94 %). 
2. The cyclization of 2-hydroxy-α-
hetarylacetophenones 
A more convenient method for the 
preparation of 3-hetarylchroman-4-ones is based 
on the ring closure of 2-hydroxy-α-
hetarylacetophenones. 
In the references [15, 16] it is shown that 
3-(2-pyridinyl)chroman-4-one N-oxides 10 and 
11 were synthesized by cyclization of 1-(2-
hydroxyphenyl)-2-(2-pyridinyl)ethanone N-
oxide 12 with 1 or 2 moles of formaldehyde 
subsequently (Scheme 5). 
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Scheme 5. The synthesis of 3-(2-pyridinyl)chroman-4-
one N-oxides. 
In the search for new compounds of 
pharmacological interest a number of 
derivatives containing the imidazole and the 
chroman ring in the same molecule were 
prepared, as exemplified in Scheme 6 [10, 11]. 
2-(1H–Imidazol-1-yl)-2’-hydroxyaceto-
phenones 13 were thus easily prepared by 
reaction of 2-bromo-2’-hydroxyacetophenones 
14 with an excess of imidazoles in DMF 
(Method A). The azole residue plays an 
important role in enhancing nucleophilic 
reactivity on the methylene group of the 
generated acetophenones. 
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Scheme 6. The synthesis of 2-(un)substituted-3-(1H-
imidazol-1-yl)chroman-4-ones.   
The ring closure of 2-(1H–imidazol-1-
yl)-2’-hydroxyacetophenones 13 to 3-(1H-
imidazol-1-yl)chroman-4-ones 15 was 
performed with paraformaldehyde in glacial 
acetic acid (Method B) with yields ranging from 
45 to 70 %. Small amount of hydroxymethyl 
derivatives 16 were formed as by-products from 
a second electrophilic attack by formaldehyde. 
FRENCH-UKRAINIAN JOURNAL OF CHEMISTRY (2015, VOLUME 3, ISSUE 1)  
8 
 
The compounds 16 could be obtained from 13 
in high yields using an excess of 
paraformaldehyde in acetic acid or preferably 
using a 40 % aqueous formaldehyde solution in 
the presence of sodium metabisulphite (Na2S2O5 
Method C). Hydroxymethyl derivatives 16 
could also be obtained from 15 itself with an 
excess of paraformaldehyde. Reaction of 2-
(1H–imidazol-1-yl)-2’-hydroxyacetophenones 
13 with other aldehydes gave 2-substituted-3-
(1H-imidazol-1-yl)chroman-4-ones 17, 
predominantly in the trans configuration as 
shown by NMR spectral analysis. Glacial acetic 
acid (Method D) or an excess of the reacting 
aldehyde (Method E) were also used as 
solvents. The yields ranged from 55 to 95 %. 
The ring closure depicted in Scheme 6 
also works well for 1-pyrazolyl derivatives [10]. 
When pyrazole reacted with 2’-hydroxy-5’-
chloro-2-bromoacetophenone under reaction 
conditions similar to those of Method A, 2-(1H-
pyrazol-1-yl)-2’-hydroxy-5’-chloroaceto-
phenone 18 was obtained. Reaction of the latter 
with acetaldehyde in acetic acid following 
Method D gave trans-6-chloro-3-(1H-pyrazol-1-
yl)-2-methylchroman-4-one 19 in 85 % yield. 
The cognate compound 6-chloro-3-(1H-pyrazol-
1-yl)chroman-4-one 20 was obtained from the 
ketone 18 and paraformaldehyde in a very dilute 
solution of acetic acid (Method F). In contrast,  
under the usual conditions reported in Method B 
for the imidazole analogues, condensation of 
two molecules of 1-pyrazolyl derivative 18 with 
formaldehyde took place giving a compound to 
which the authors [10] assigned the structure of 
3-(1H-pyrazol-1-yl)-3-(2-(2-hydroxy-5-
chlorobenzoyl)-2-(1H-pyrazol-1-yl)ethyl-6-
chlorochroman-4-one 21 (Scheme 7). 
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Scheme 7. The synthesis of 3-(1H-pyrazol-1-yl)chroman-
4-ones.   
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Scheme 8. The synthesis of 2-methyl-3-(1-methyl-1H-
imidazol-2-yl)chroman-4-one. 
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The synthesis of 2-methyl-3-(1-methyl-
1H-imidazol-2-yl)chroman-4-one 22 has been 
described [17] starting from 2-acetoxy-5-
chlorobenzoyl chloride and 1,2-
dimethylimidazole (Scheme 8). The 
intermediate chromone 23 here undergo alkaline 
ring opening to the corresponding 1-(2-hydroxy-
5-chlorophenyl)-2-(1-methyl-1H-imidazol-2-
yl)ethenole 24. The latter in the presence of 
acetaldehyde in acetic acid at 90
0 
C
 
gives ring 
closure to the desired chroman-4-one 22 in pure 
trans form.  
The isomeric 3-(1,2,4-triazolyl)chroman-
4-ones with an (un)substituted position 2 were 
synthesized through a similar procedure which 
was employed for diazolyl analogues of 
isoflavanones. The apparent straight-forward 
preparation of 2-hydroxy--
triazolylacetophenone was performed by 
displacement of 2-bromo-2’-
hydroxyacetophenones 14 by 1,2,4-triazole as 
reported by Baji et al. [18]. 
Treatment of 14 with an excess of 1,2,4-triazole 
in DMF gave a mixture of isomeric 2-hydroxy-
-triazolylacetophenones 25 and 26 in 1:2 ratio 
[12]. In addition, a quaternary triazolium salt, 
the by-product 27, was isolated in 45-50 % 
yield. Direct alkylation of 1,2,4-triazole usually 
affords a mixture of mainly 1- and some 4-
substituted products (Scheme 9). The selectivity 
varies with the nature of the alkylating agent 
and the conditions employed, but ranges from 
70:30 to 90:10 [19]. The problem of preparing 
α-(1H-1,2,4-triazol-1-yl)acetophenones 25 in 
high yield was solved as indicated in Scheme 
10. 
Reaction of 4-amino-1,2,4-triazole 8 with 2-
bromo-2’-hydroxyacetophenones 14 gave pure 
samples of the triazolium salt 28, which on 
subsequent deamination with nitrous acid 
yielded exclusively the 1-substituted product 25. 
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Scheme 9. The synthesis of isomeric 2-hydroxy-α-triazolylacetophenones.
FRENCH-UKRAINIAN JOURNAL OF CHEMISTRY (2015, VOLUME 3, ISSUE 1)  
10 
 
 
OH
N
N
N
O
R
NH
2
OH
N
N
O
R
NH
2
N
 
N N
N
NH
2
28
i-PrOH
+ +
Br -
R=H 75 %
R=Cl 64 %
HONO
25
14
89-95 %
 
Scheme 10. The synthesis of 2-hydroxy-α-(1H-1,2,4-triazol-1-yl)acetophenones.  
 
Ring closure of the isomeric 2-hydroxy-α-
triazolylacetophenones 25 and 26 (Scheme 11) 
by paraformaldehyde in acetic acid at 90-100C 
gave the corresponding 3-triazolylchromanones 
29 and 30 in low to moderate yield [12, 20, 21].  
In the latter reaction in addition to 3-(4H-1,2,4-
triazol-4-yl)chroman-4-ones 30, the 
corresponding hydroxymetyl derivatives 31 
were obtained as by-products [12]. 
 
OH
O
N
N
N
R
O
N
N
N
R O
O
O
MeR
N
N
N
OH
O
N
N
N
R
O
N
N
N
R O
O
O
N
OH
N
N
R
O
O
MeR
N
N
N
HCHO
MeCHO
AcOH
AcOH
25
29
32
R=Cl 40 %
HCHO
MeCHO
AcOH
26
30
31 
+
R=H 70 %
R=Cl 51 %
R=H 12 %
R=Cl 15 %
AcOH
33 
 
Scheme 11 The synthesis of isomeric 2-(un)substituted 3-(1,2,4-triazolyl)chroman-4-ones. 
Analogous ring closure by acetaldehyde gave 2-
methyl-3-(1,2,4-triazolyl)chroman-4-ones 32 
and 33, where the configuration of the methyl 
group with  respect to azole ring was assigned to 
a trans configuration, according to the quite 
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large 
1
H NMR coupling constant (J =11,6-12,0 
Hz) [20, 22]. 
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Scheme 12. The synthesis of 3-isoxazolylchroman-4-one derivatives. 
 
The publications [23, 24] present 
information on the synthesis directed towards 
the fungal xanthone bikaverin. It is herein 
reported about 3-isoxazolylchroman-4-one 
derivatives 34 obtained, according to the 
method depicted in Scheme 12.  
At first, the authors of the review have 
successfully used bisdimethylamino-methane in 
ethanol for the cyclization of the 2-hydroxy-4- 
methoxy- α-(quinolin-2-yl)acetophenone 35 into 
the corresponding 3-(quinolin-2-yl)chroman-4-
one 36 in 80 % yield (Scheme 13). Work on this 
reaction is still in progress, especially aimed at 
extending the synthesis to other 3-
hetarylchroman-4-ones. 
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35
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(80 %)   
Scheme 13. The synthesis of 7-methoxy-6-ethyl-3-
(quinolin-2-yl)chroman-4-one. 
 
 
3. Hydrogenation of 3-hetarylchromones 
When a chromone is subjected to 
hydrogenation/reduction, several products can 
be isolated: chroman-4-ones, chroman-4-ols, 
chromenes and chromans. 
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The reduction of chromones represents 
an important method for the synthesis of 
chroman-4-ones. Many methods of selective or 
unselective reduction of such compounds have 
been reported: with palladium on charcoal or 
other supports, or elemental palladium; with 
platinum, with Raney-nickel; with hydride 
complexes, with DIBAL-H or with 
homogeneous hydrogenation catalysts, etc. [5]. 
Some of them were used for the hydrogenation 
of 3-hetarylchromones. 
3.1. With palladium on carbon  
Hydrogenation on Pd/C is the most 
widely used method for reduction of chromones. 
At first, selective hydrogenation of the 
isoflavones was accomplished by Szabo et al. 
[25, 26]. The selectivity in the formation of 
dihydro-isoflavones was found dependent on the 
supplier of Pd/C and pH-dependent. 
A starting point for hydrogenation of an 
unknown chromone can be a “titration with 
hydrogen” over Pd/C. A problem with this 
method is a strong dependence of the 
hydrogenation feasibility on substrate and on 
hydrogen pressure. 
A successful application of “titration 
with hydrogen” is illustrated by Khilya et al., 
who showed that the 3-(2-pyridyl)-7-
hydroxychromone 37 could be hydrogenated to 
3-(2-pyridyl)-7-hydroxychroman-4-one 38 by 
allowing 1 equivalent of hydrogen to be 
absorbed (Scheme 14). 
The purification of the hydrogenated 
product 38 from admixtures was carried out 
after acylation with acetic anhydride in pyridine 
at room temperature and subsequent 
crystallization from absolute ethanol. In 
consequence the acylated hydrogenated product 
39 satisfied the chromatographic purity and the 
availability of two acetic groups by the data of 
elemental analysis.  
Catalytic hydrogenation of 7-acetoxy-3-
(2-pyridyl)chromone 40 in alcoholic solution to 
the corresponding chroman-4-one 41 followed 
by treatment with acetic anhydride resulted in 
the same diacetate 39. 
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Scheme 14. Catalytic hydrogenation of 3-(2-pyridyl)chromone derivatives. 
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Scheme 15. The synthesis of 6-ethyl-7-methoxy-3-(quinolin-2-yl)chroman-4-one.                                   
The same strategy was applied for the 
conversion of 3-(2-quinolyl)-6-ethyl-7-
methoxychromone 42 into 3-(2-quinolyl)-6-
ethyl-7-methoxychroman-4-one 36 (Scheme 
15). The latter was identical to the sample 
obtained by cyclization of 2-hydroxy-4-
methoxy-α-(quinolin-2-yl)acetophenone with 
bisdimethylamino-methane.  
        A patent [27] reports on the hydrogenation 
of 6-epoxyethyl-3-(1H-tetrazol-5-yl)chromone 
to 6-hydroxyethyl-3-(1H-tetrazol-5-
yl)chromone using palladium black or 5 % Pd 
on activated carbon at r.t. or 100C. Only the 
epoxide ring was hydrogenolized, while the 
chromone double bond was not reduced.  
Catalytic hydrogenation of 3-
piperidinochromone 43 in 0.2 N hydrochloric 
acid with 10% Pd on carbon powder at r.t. 
resulted in 3-piperidinochromanol 44 [8] 
(Scheme 16).  
O
N
O
43
44
O
N
O
2
0.2 N HCl 0.1 N HCl
1 mole H2
Pd/C
2 mole H2
Pd/C
OH
N
O
 
Scheme 16. The synthesis of 3-piperidinochromanol.  
 
3.2 Transfer hydrogenation   
In the chromone series, catalytic transfer 
hydrogenation (CTH) is an efficient alternative 
to catalytic hydrogenation. This type of 
hydrogenation does not involve hydrogen in 
gaseous form, but calls for other reducing 
agents. 
         3-Imidazolylchromone 45 was thus 
reduced to the corresponding chromanone 4 
[28] in 53 % yield by transfer hydrogenation in 
aqueous ethanol using the sodium 
hypophosphite-palladium catalyst reducing 
system, first described by Entwistle I.D. et al. 
[29] (Scheme 17). 
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Scheme 17. The synthesis of 3-imidazolylchroman-4-one.  
 
3.3 Reduction with complex of hydrides 
According to information about the 
reduction of chromones with hydride complexes 
of aluminium and boron, the typical product of 
reduction are chromanols or chromans (after 
elimination of water from chromanols). 
Chroman-4-ones are generally not stable in the 
presence of complex hydrides and undergo 
further reduction. In confirmation of this 
statement, one may cite the synthetic pathway 
starting from 3-(1H-imidazol-1-yl)chroman-4-
one 15 leading to the corresponding 3-(1H-
imidazol-1-yl)chroman-4-ol (cis-trans mixture) 
46 and 3-(1H-imidazol-1-yl)chromen 47 [10] 
(Scheme 18).  
O
N
O
N
MeO
15
OH
N
O
N
MeO
46
N
O
N
MeO
47
H +
NaBH
4
 
Scheme 18. Hydrogenation of 3-(1H-imidazol-1-
yl)chroman-4-one.  
 
Cozzi et al. [17, 28] have studied the reduction 
of (un)substituted 3-(1H-imidazol-1-yl)- and 3-
(N-methylimidazol-2-yl)chromones. The 3-(1H-
imidazol-1-yl)chromones 48 were thus reduced 
with sodium borohydride to the corresponding 
chromanols 4 or 17 in high yields (Scheme 19). 
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OH
N
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R
NaBH
4
MeOH
48
4. (96 %)
5-10 oC
,
17.
 R=H
R= CO2Et (87 %)
4,17
 
 
Scheme 19. Hydrogenation of 3-(1H-imidazol-1-
yl)chromone.                                                                                           
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This reaction was attempted with imidazol-2-yl 
analogues 49 and the corresponding chromanols 
50 were obtained in high yields as well 
(Scheme 20). They were obtained in the trans-
trans configuration as indicated by NMR 
spectral analysis. 
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N51
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H
2
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Scheme 20. Hydrogenation of 2-methyl-3-(1-
methylimidazol-2-yl)chroman-4-ones. 
 
The chromanols 50 could be easily dehydrated 
to the chromenes 51 by heating in acetic acid in 
the presence of concentrated sulphuric acid or 
concentrated hydrobromic acid, in which case 
concomitant demethylation took place (6-MeO 
to 6-OH).  
Khilya et al. have also studied the 
reduction of 3-(2-pyridyl)-7-methoxychromone 
52 with sodium borohydride leading to 3-(2-
pyridyl)-7-methoxychroman-4-ol, which was 
isolated in practical quantitative yield as a 
mixture of cis- and trans- geometrical isomers 
53 and 54 (Scheme 21).  
 
 
O
N
OMeO
52
OH
N
OMeO
OH
N
OMeO
53
+
cis-
trans-
NaBH
4
54
 
Scheme 21. Hydrogenation of 7-methoxy-3-(pyridin-2-
yl)chromen-4-one.  
 
The mixture of geometrical isomers was 
resolved (in cis- 53 and trans- 54) by TLC on 
the silicagel plates. Confirmation of the 
stereochemical configuration and establishment 
of the tetrahydropyranes conformation were 
evidenced by NMR spectral data. 
 
3.4 Homogeneous hydrogenation 
            Homogeneous catalytic hydrogenation is 
an important tool for the chemistry of chroman-
4-ones since it could proceed enantioselectivity. 
Catalytic homogeneous hydrogenation of 
7-methoxyisoflavone [30-32] and its pyridine 
analogues [31, 32] was first achieved in the 
presence of cationic iridium complexes. 
The 7-methoxy-3-(pyridin-2-
yl)chromone 52 contains a very electron-
deficient C=C-bond, since the pyridine ring is 
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electron acceptor. Because of its unique 
electronic and steric properties, it was 
challenging to check the homogeneous 
hydrogenation outcome of this compound.  
7-Methoxy-3-(pyridin-2-yl)chromone 52 
was actually efficiently homogeneously 
hydrogenated under either electrophilic or 
nucleophilic conditions (under hydrogen 
pressure of 100 bar).  
The conversion of 52 in presence of 1 
mole-% [Ir(COD)(i-Pr-Phox)]BARF was 90 % 
under nucleophilic conditions, and the use of 1,5 
mole-% catalyst gave the 3-(pyridin-2-
yl)chroman-4-one 55 in 99 % yield (after 
column chromatography) (Scheme 22) .  
           Hydrogenation of the chromone 52 under 
electrophilic conditions proved to be even more 
effective. It was thus observed that the use of 
iridium complexes such as [Ir(COD)((R)-
BINAP)]BARF, [Ir(COD)(PPh3)2]BARF, 
[Ir(COD)(PCy3)(Py)]PF6, [Ir(COD)((rac)-  
BINAP)]BARF or [Ir(cod)(i-Pr-Phox)]BARF 
(in 1 mole-%) in such solvents as THF, CH2Cl2, 
PhMe or MeOH resulted in 100 % convertion of 
the chromone 52. 7-Methoxy-3-(pyridin-2-
yl)chroman-4-one 55 was isolated in 94-96% 
yield after column chromatography  (Scheme 
23). 
O
N
OMeO
52
O
N
OMeO
55
[Ir(COD)(4S)-i-Pr-Phox]BARF
toluene, DIPEA
H2
 
Scheme 22. Homogeneous hydrogenation of 2-methoxy-
3-(pyridin-2-yl)chromen-4-one under nucleophilic 
conditions. 
 
O
N
OMeO
O
N
OMeO
O
OMeO
H
N
52
55
[Ir(COD)(PAN)]X 
toluene
H2
X=PF6, BARF
(94-96 %)
 Scheme 23. Homogeneous hydrogenation of 7-methoxy-
3-(pyridin-2-yl)chromen-4-one under electrophilic 
conditions. 
 
Complexes of rutenium left 7-methoxy-3-
(pyridin-2-yl)chromone 52 intact and complexes 
of rhodium were not effective.  
The enantiomers of the 3-(pyridin-2-
yl)chroman-4-one 55 were not totally resolved 
(to baseline) on analytical chiral HPLC. The 
reason of this failure for resolution is an 
FRENCH-UKRAINIAN JOURNAL OF CHEMISTRY (2015, VOLUME 3, ISSUE 1)  
17 
 
enolization process occurring even in unpolar 
solvents. The use of the chiral lantanoid shift 
reagent Eu(tfc)3 resulted in a splitting of 
1
H 
NMR resonance frequencies of the two 
enantiomers. Nevertheless, NMR analysis under 
such resolving conditions of 3-(pyridin-2-
yl)chroman-4-one 55, obtained in presence of 
chiral nonracemic catalysts, showed that the 
product was generated in racemic form. This is 
not surprising, as the chromanone 55 is prone to 
undergo enolization, which deletes the chiral 
center. The enolization process is spontaneous, 
without requiring any additive (e.g. bases or 
acids) and occurs readily at r.t. Enolization of 
the chromanone 55 is indeed favored by the 
formation of a new hydrogen bond (Scheme 
23). Enolization takes place even in low polar 
solvents (C6D6, CDCl3 or in THF-D8) and in 
solid state and makes the enantiomerically pure 
chromanone 55 unavailable  
 
4. Other methods for the synthesis of 3-
hetarylchroman-4-ones 
 
Litkei et al. [33] have performed an easy 
and convenient method for the synthesis of the 
hitherto unknown trans-2-phenyl-3-
tetrazolylchroman-4-one 56 (Scheme 24). 
Trans-3-aminoflavanone 57 is known to be 
stable only in the form of its hydrochloride  
reacts with sodium azide and ethyl ortoformiate 
in hot acetic acid to afford trans-2-phenyl-3-
tetrazolylchroman-4-one 56 in 59 % yield. The 
starting 3-aminoflavanone 57 [34] was readily 
obtained by application of the Neber reaction to 
4-oximinoflavan tosylate.  
O
NH
2
O
O
N
O
N
N
N
HC(OEt)
3
NaN
3
, AcOH
56
57
*HCl
4h,
 
Scheme 24. The synthesis of trans-2-phenyl-3-
tetrazolylchroman-4-one.  
 
Biological activity of 3-hetarylchroman-4-
ones  
3-Hetarylchroman-4-ones exhibit an 
interesting spectrum of biological activity. 
            Just so, 3-(2-pyridinyl)chroman-4-one 
N- oxides possess antiulcer activity in rats at 10-
100 mg/ kg [16]. 
A series of 3-(1-imidazolyl)chroman-4-
ones were tested and a family of hypolipidemic 
agents with unusual positive features were 
identified [11]. In rats submitted to an 
atherogenic diet, 3-(1-imidazolyl)chroman-4-
ones, bearing appropriate lipophilic substituents 
on the phenyl ring, were found to induce a 
lowering of the total cholesterol, markedly 
lowering LDL and raising HDL. This activity 
was accompanied by an increase in liver weight, 
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which was correlated to some degree, with 
microsomal induction but not with peroxisome 
proliferation. On the other hand, hypolipidemic 
and peroxisome proliferators agents (e.g. 
clofibrate and related compounds) lowered total 
serum cholesterol but failed, in normolipemic 
rats, to raise the HDL/LDL ratio to the same 
extent as described for 3-(1-
imidazolyl)chroman-4-ones. Derivatives of 3-
(1-imidazolyl)chroman-4-one were patented for 
a use in prevention and therapy of 
atherosclerosis, owing to inhibition of blood 
platelet aggregation, increase total serum HDL 
cholesterol, increase of the ratio between -
lipoprotein and -lipoprotein total cholesterol, 
and/or reducing total serum cholesterol or serum 
triglycerides [35]. 
A series of 3-azolylchroman-4-one 
derivatives was aimed at investigating 
anticonvulsant activity [20], owing to the fact 
that these compounds are conformationally 
constrained analogs of (arylalkyl)azole 
anticonvulsants (loreclezole, nafimidone, 
denzimole). The anticonvulsant activities were 
evaluated by determining seizure latency and 
protective effect against pentylenetetrazole 
(PTZ)-induced lethal convulsion in mice at a 
dose of 5 mg/kg, where sodium valproate at a 
dose of 150 mg/kg was taken as a reference 
treatment. Among the examinated compounds, 
7-chloro-3-(1H-imidazol-1-yl)chroman-4-one 
and 3-(1H-1,2,4-triazol-1-yl)chroman-4-one 
exhibited significant activity in delayin seizures 
as well as effective protection against PTZ-
induced seizures and deaths. No effective 
compound was identified in the triazol-4-yl 
series. It has often been stated that seizures 
induced by PTZ can be suppressed by drugs that 
reduce T-type Ca
2+
 currents, such as 
ethosuximide, and drugs that enhance GABAA 
receptor-mediated inhibitory neuro-
transmission, such as benzodiazepines or 
phenobarbital. So it is possible that the 
azolylchroman-4-ones exert their anticonvulsant 
action by modulation of Ca
2+
 currents or 
GABAA receptor. As anticonvulsant agents that 
inhibit seizures induced by PTZ 3-
azolylchroman-4-ones can be considered 
effective in the treatment of generalized 
myoclonic and absence seizures.  
In addition, 3-azolylchroman-4-ones are 
intermediates in the design of some antifungal 
agents [20-22, 36]. 
 
Conclusions   
In conclusion, a variety of approaches to the 
synthesis of 3-azahetarylchroman-4-ones has 
been presented and discussed in view of their 
advantages and disadvantages as well as trends 
for their future development. This review 
highlights that the researches in the field of 3-
azahetarylchroman-4-ones is both of theoretical 
and practical significance. Gathered in the same 
molecule, N-containing heterocycles and 
chromanone cores represent a useful source for 
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the discovery of novel physiologically active 
compounds. 
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